Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study

Yingying Du, Qisheng Cao, Congqiao Jiang, Hui Liang, Zhongliang Ning, Chushu Ji, Jinguo Wang, Chaoping Zhou, Zonghui Jiang, Changjun Yu, Lei Li, Yong Zhao, Yuemei Xu, Tengyun Xu, Wenjun Hu, Daoqin Wang, Huaidong Cheng, Guihe Wang, Jinhua Zhou, Song Wang, Yanshun Zhang, Zhiqiang Hu, Xinzhong Li, Donghui Lu, Jun Zhang, Hua Xie, Guoping Sun, Yingying Du, Qisheng Cao, Congqiao Jiang, Hui Liang, Zhongliang Ning, Chushu Ji, Jinguo Wang, Chaoping Zhou, Zonghui Jiang, Changjun Yu, Lei Li, Yong Zhao, Yuemei Xu, Tengyun Xu, Wenjun Hu, Daoqin Wang, Huaidong Cheng, Guihe Wang, Jinhua Zhou, Song Wang, Yanshun Zhang, Zhiqiang Hu, Xinzhong Li, Donghui Lu, Jun Zhang, Hua Xie, Guoping Sun

Abstract

Apatinib has been demonstrated to be effective and safe among patients with gastric cancer failing after at least two lines chemotherapy. This study aimed to evaluate its effectiveness and safety of low-dose apatinib for the treatment of gastric cancer in real-world practice. We performed a prospective, multicenter observation study in a real-world setting. Patients with advanced gastric cancer more than 18 years old were eligible and received low-dose apatinib (500 mg or 250mg per day) therapy. The median progression-free survival (PFS), median overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety were assessed. Between September 2017 and April 2019, a total of 747 patients were enrolled. The mPFS was 5.56 months (95% CI 4.47-6.28), and mOS was 7.5 months (95% CI 6.74-8.88). Four patients achieved complete response, 47 achieved partial response, and 374 patients achieved stable disease. The ORR was 6.83% and DCR was 56.89%. In addition, multivariate Cox regression analysis indicated that hand-foot syndrome was one independent predictor for PFS and OS. The most common adverse events (AEs) at any grade were hypertension (36.55%), proteinuria (10.26%), hand-foot syndrome (33.53%), fatigue (24.9%), anemia (57.35%), leukopenia (44.49%), thrombocytopenia (34.21%), and neutropenia (53.33%). Grade 3-4 AEs with incidences of 5% or greater were anemia (13.97%), thrombocytopenia (7.14%), and neutropenia (6.67%). No treatment-related death was observed during the treatment of apatinib. The prospective study suggested that low-dose apatinib was an effective regimen for the treatment of advanced gastric cancer with tolerable or controlled toxicity in real world. Trial registration: NCT03333967.

Keywords: advanced gastric cancer; apatinib; real-world.

Conflict of interest statement

All authors declare no potential conflict of interest.

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7‐34.
    1. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700‐713.
    1. Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513‐1518.
    1. Nowak‐Sliwinska P, Alitalo K, Allen E, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018;21(3):425‐532.
    1. Li J, Qin S, Xu J, et al. Apatinib for chemotherapy‐refractory advanced metastatic gastric cancer: results from a randomized, placebo‐controlled, parallel‐arm, phase II trial. J Clin Oncol. 2013;31(26):3219‐3225.
    1. Li J, Qin S, Xu J, et al. Randomized, double‐blind, placebo‐controlled phase III trial of apatinib in patients with chemotherapy‐refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448‐1454.
    1. Sun G‐P, Li D, Ning Z, et al. . Exploration of patients with gastric cancer who benefit from apatinib: An updated real‐world study. J Clin Oncol. 2019;37(4_Suppl):161.
    1. Sun G, Li D, Ning Z, et al. A real world study of apatinib treatment in gastric cancer: current status and clinical benefit. Ann Oncol. 2018;29(Suppl 8):mdy282.067.
    1. Kim GM, Jeung H‐C, Rha SY, et al. A randomized phase II trial of S‐1‐oxaliplatin versus capecitabine‐oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48(4):518‐526.
    1. Kang Y‐K, Kang W‐K, Shin D‐B, et al. Capecitabine/cisplatin versus 5‐fluorouracil/cisplatin as first‐line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666‐673.
    1. Al‐Batran S‐E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435‐1442.
    1. Bang Y‐J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet. 2010;376(9742):687‐697.
    1. Qiu H, Zhou Z. Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5. Zhonghua Wei Chang Wai Ke Za Zhi. 2018;21(2):160‐164.
    1. Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5‐fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first‐line chemotherapy. Cancer Chemother Pharmacol. 2013;71(2):481‐488.
    1. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro‐oesophageal junction adenocarcinoma (RAINBOW): a double‐blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224‐1235.
    1. Zhang Y, Han C, Li J, et al. Efficacy and safety for apatinib treatment in advanced gastric cancer: a real world study. Sci Rep. 2017;7(1):13208.
    1. Huang L, Wei Y, Shen S, et al. Therapeutic effect of apatinib on overall survival is mediated by prolonged progression‐free survival in advanced gastric cancer patients. Oncotarget. 2017;8(17):29346‐29354.
    1. Liu X, Qin S, Wang Z, et al. Early presence of anti‐angiogenesis‐related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10(1):153.
    1. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro‐oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo‐controlled, phase 3 trial. Lancet. 2014;383(9911):31‐39.
    1. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. J Clin Oncol. 2011;29(30):3968‐3976.
    1. Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab combined with FOLFOX as front‐line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double‐blind, multicenter phase II trial. Ann Oncol. 2016;27(12):2196‐2203.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться